Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT

Although the newly developed second-generation anti-androgen drug enzalutamide can repress prostate cancer progression significantly, it only extends the survival of prostate cancer patients by 4–6 months mainly due to the occurrence of enzalutamide resistance. Most of the previous studies on AR ant...

詳細記述

保存先:
書誌詳細
出版年:Cell Death Dis
主要な著者: Liu, Qiuli, Tong, Dali, Liu, Gaolei, Xu, Jing, Do, Khang, Geary, Kyla, Zhang, Dianzheng, Zhang, Jun, Zhang, Yao, Li, Yaoming, Bi, Gang, Lan, Weihua, Jiang, Jun
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 2017
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5596596/
https://ncbi.nlm.nih.gov/pubmed/28837141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2017.417
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料